Hitachi, Japan

Shunsuke Ishikawa

This inventor holds 1 USPTO granted patent. Top assignee: Ares Trading S.a.. Active years: 2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shunsuke Ishikawa. Retrieved from https://idiyas.com/inventor/shunsuke-ishikawa-lc3od0b1

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 62(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Shunsuke Ishikawa: Innovator in Drug Delivery Technology.

Introduction

Shunsuke Ishikawa is a notable inventor based in Hitachi, Japan. He has made significant contributions to the field of drug delivery devices. His innovative approach has led to the development of a unique patent that enhances the efficiency of drug delivery systems.

Latest Patents

Ishikawa holds a patent for a "Connection station for drug delivery devices." This invention aims to improve the functionality and reliability of drug delivery mechanisms, ensuring that patients receive their medications more effectively.

Career Highlights

Shunsuke Ishikawa is currently employed at Ares Trading S.A., where he continues to work on advancements in medical technology. His dedication to innovation has positioned him as a key figure in the industry.

Collaborations

Ishikawa collaborates with Alun Wilcox, leveraging their combined expertise to push the boundaries of drug delivery technology.

Conclusion

Shunsuke Ishikawa's contributions to the field of drug delivery devices exemplify the impact of innovative thinking in healthcare. His work continues to pave the way for advancements that benefit patients worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…